Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VB10.NEO + bempegaldesleukin
- Development stage
- Unknown
- Lead developer
- Nykode Therapeutics
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intramuscular (VB10.NEO), Intravenous (bempegaldesleukin)
01
Overview
**VB10.NEO + bempegaldesleukin** is a combination of two investigational immunotherapy products for cancer treatment. **VB10.NEO** is a personalized DNA cancer vaccine that aims to stimulate T cell responses against patient-specific neoantigens, whereas **bempegaldesleukin** is a pegylated interleukin-2 (IL-2) cytokine prodrug designed to selectively expand CD8+ effector T cells and natural killer (NK) cells in the tumor microenvironment, thereby enhancing antitumor activity. The combination is being studied primarily in oncology settings where robust immune activation is desired, leveraging the vaccine-induced T cells (from VB10.NEO) and their expansion/activation (by bempegaldesleukin). The principal developers are Nykode Therapeutics (for VB10.NEO) and Nektar Therapeutics (for bempegaldesleukin), with clinical development focusing on various solid tumors.
02
Targets
CCR1CCR5 (C-C chemokine receptor type 5)IL2RB (IL-2 receptor beta chain)pMHC-I (Peptide–MHC class I complex)
Beyond the preview
Go deeper on VB10.NEO + bempegaldesleukin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VB10.NEO + bempegaldesleukin.